

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CLARITY MEDICAL GROUP HOLDING LIMITED

清晰醫療集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1406)

ESTABLISHMENT OF SEPARATE SPECIAL COMMITTEE AND CONTINUED SUSPENSION OF TRADING

Reference is made to the announcement of Clarity Medical Group Holding Limited (the “**Company**”) dated 13 May 2025 (the “**Announcement**”) in relation to, among other matters, certain purported allegations against the Company and the establishment of a separate special investigation committee. Unless otherwise stated, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

In addition to the information contained in the Announcement, the Board would like to provide the below supplemental information in relation to the Separate Special Committee.

MEMBERSHIP OF THE SEPARATE SPECIAL COMMITTEE

A majority of the Board resolved on 25 June 2025, that the Separate Special Committee shall comprise Mr. Lee Kam Hung Lawrence, BBS, JP (“**Mr. Lee**”), Ms. Cheng Jessica, Mr. Wang Can and Ms. Ci Ying. With Mr. Lee acting as the chairman of the Separate Special Committee. The Board further announces that on 1 July 2025, the Company appointed Mr. Lee as an external independent legal expert.

The biographical details of Mr. Lee are set out as follows:

Mr. Lee had practiced with Baker McKenzie, an international law firm (the “**Firm**”), since 1979. He served as the Chairman of the Firm’s Hong Kong and PRC offices from 1996 to June 2024 and as a member of the Firm’s Capital Markets Practice Group, where he mainly focused on corporate finance, including mergers and acquisitions of public companies, corporate reorganization, securities-related practices, and assisting companies with their compliance issues and challenges. In the last decade, he also began focusing on substantial dispute resolution work and represented clients in several high-profile cases. Mr. Lee also served as Chairman of the Asia Pacific Regional Council and was a former Executive Committee member of the Firm. He retired in September 2024 after practicing for 46 years at the Firm.

Mr. Lee graduated from the University of Hong Kong with a Bachelor's degree in Laws in 1978 and a Postgraduate Certificate in Laws in 1979. He is admitted as a solicitor in Hong Kong, New South Wales and Victoria, and as a solicitor (non-practising) in England and Wales.

TERMS OF REFERENCE

As at the date of this announcement, the Board is still in the process of determining the terms of reference of the Separate Special Committee.

CONTINUED SUSPENSION OF TRADING

Trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on Tuesday, 15 April 2025 and will remain suspended until further notice.

Shareholders and potential investors of the Company should exercise caution when dealing in the shares or other securities of the Company, and if they are in any doubt about their position, they should consult their independent professional adviser(s).

By Order of the Board
CLARITY MEDICAL GROUP HOLDING LIMITED
WU Ting Yuk Anthony
Non-Executive Director and Chairman

Hong Kong, 3 July 2025

As at the date of this announcement, the Board comprises Mr. JIANG Bo, Mr. HUI Yung Chris, Dr. TSE Wai Ip and Mr. LO Tsz Hong as executive Directors, Mr. WU Ting Yuk Anthony as Chairman and non-executive Director and Ms. CHENG Jessica, Mr. WANG Can and Ms. CI Ying as independent non-executive Directors.